Schistosomiasis is a neglected but widespread tropical disease caused by infection with parasitic blood flukes. *Schistosoma mansoni*, *Schistosoma haematobium*, and *Schistosoma japonicum* are the most widely distributed species and cause the highest disease burden, particularly in sub-Saharan Africa.\(^1\) Praziquantel (PZ) is the only drug available for treatment of this disease, and it is active against adult schistosomes, but has little activity against the juvenile schistosomula, the young developmental stages of the parasite.\(^2\) Should serious praziquantel drug resistance arise, there are no viable alternatives to this drug. Even so, drug discovery for schistosomiasis has languished.

The introduction of PZ in 1982 likely led to decisions to abandon the development of a number of promising antischistosomal agents that were discovered in the same time period. One of these was Ro 13-3978 (AH01), the lead compound from a series of aryl hydantoins that were investigated in some detail at Hoffmann La-Roche.\(^3\) A number of these aryl hydantoins had high oral efficacy in schistosome animal models,\(^5\) but they also produced antiandrogenic side effects in the host,\(^3\) a not unexpected outcome given the close structural similarity of these aryl hydantoins to the antiandrogenic drug nilutamide (Figure 1). We recently showed\(^6\) that nilutamide, but not the three structurally diverse androgen receptor (AR) antagonists flutamide, bicalutamide, and cyproterone acetate, has antischistosomal activity. As phylogenetic evidence indicates that schistosome species do not appear to have ARs,\(^10\) the data led us to hypothesize that for aryl hydantoins and related heterocycles, the structural requirements for antischistosomal efficacy and AR binding interactions are divergent.

Based on the limited elucidation of the structure-activity-relationship of this aryl hydantoin compound series,\(^8\) we began to test this hypothesis by the synthesis\(^8,11\) of AH01, its imino isostere AH02, and two derivatives (AH03 and AH04) incorporating nitrile functional groups (present in bicalutamide and other antiandrogens) known to import high AR binding affinity.\(^12\) We now present our initial characterization of the antischistosomal versus antiandrogenic properties of these four aryl hydantoins.

Interaction of the aryl hydantoins with the AR was characterized by a ligand competition scintillation proximity assay\(^13\) using a hexahistadine-tagged AR-ligand binding domain (LBD). Briefly, to each well of a 96-well Ni-chelate-coated Flashplate was added 80 \(\mu\)L of 5 \(\mu\)M AR-LBD in the assay buffer (25 mM HEPES, pH 7.2, 50 mM NaCl, 0.01% NP-40, 20 \(\mu\)M dihydrotestosterone [DHT], 2% dimethyl sulfoxide [DMSO]). After 60 min incubation, the protein solution was discarded followed by washes with assay buffer. Then, 40 \(\mu\)L of serially diluted aryl hydantoins in assay buffer containing 10% DMSO were added into each well followed by addition of 40 \(\mu\)L of 20 nM \([^3H]-DHT\) in assay buffer. The final assay solutions contained 5% DMSO. After sealing the plates and equilibrating for 18 h at 4°C, radio counts were measured and IC\(_{50}\) values were calculated.

As expected, for the homologous DHT competition experiment, we measured a low IC\(_{50}\) value of 76 nM, similar to the previously reported\(^13\) value of 57 nM. Nilutamide and AH03 had IC\(_{50}\) values of 7.4 and 1.5 \(\mu\)M, respectively, whereas the other aryl hydantoins had IC\(_{50}\) values > 27 \(\mu\)M. The binding competition observed for nilutamide and AH03 is consistent with previous data showing that AR ligands with aryl nitro or nitrile functional groups can form ion-dipole interactions with R752 in the AR ligand-binding domain.\(^12\)

To put the AR ligand competition data in context, we assessed the effects of the aryl hydantoins on androgen-dependent LNCaP C-33 human prostate cancer cells.\(^14\) Briefly, LNCaP cells (passage nos. between 39 to 42) were plated at a density of 5 \(\times\) 10\(^4\) or 6 \(\times\) 10\(^4\) cells/well in 6-well plates for 72 h in a regular RPMI 1640 culture medium containing 5% fetal bovine serum (FBS), which was maintained at 37°C in a humidified atmosphere of 5% CO\(_2\). This was followed by continued cell culture for 48 h in a steroid-reduced medium consisting of phenol red-free RPMI 1640 containing 5% charcoal/dextran-treated FBS (v/v), 2 mM glutamine, and 50 \(\mu\)g/mL gentamicin. Cells were then exposed for an additional 72 h to 10 \(\mu\)M test compounds (from 10 mM DMSO stock solutions) with or without DHT (10 nM) after which time cell numbers were counted and cell growth relative to that of control cells was determined.

As expected, DHT significantly induced LNCaP cell proliferation, and this was blocked by the antiandrogen bicalutamide (\(P < 0.0001\)) (Figure 2). Similarly, AH01 and AH02 blocked DHT-induced LNCaP cell proliferation (\(P < 0.001\), but these
compounds had no effect on basal cell growth. Conversely, nilutamide, AH03, and AH04 alone stimulated LNCaP cell growth ($P < 0.001$), and for nilutamide, addition of DHT decreased ($P < 0.05$) cell proliferation. These data indicate that nilutamide, AH03, and AH04 are AR agonists in this cell line. This is consistent with previous data$^{15}$ revealing that nilutamide acts as an AR agonist in LNCaP cells, presumably as a consequence of the T868A mutation in the ligand-binding domain of the AR expressed in this cell line. It is also possible that DHT may trigger a shutoff mechanism after maximal cell proliferation, consistent with previous results that LNCaP cells can respond to androgens in a biphasic concentration-dependent response.$^{16,17}$ For these hydantoins, the apparent discrepancies between the ligand competition scintillation proximity assay and LNCaP cell proliferation data may also be the result of a differential antagonistic effect on tetrameric AR interaction with androgen response elements in LNCaP

For AH01, nilutamide, and the other aryl hydantoins, there was no measurable interaction with the AR in a ligand competition assay, but it did block DHT-induced cell proliferation that DHT may trigger a shutoff mechanism after maximal cell proliferation. For these hydantoins, the apparent activities of AH01 and AH02 were conserved with 100 and 200 mg/kg oral doses of AH01 and AH02, administration of single 200 mg/kg oral doses of AH03 and AH04 to $S. mansoni$-infected or uninfected mice led to the death of 60–100% of all animals within 4–5 days post-treatment. The observed toxicity of these two aryl hydantoins, the lack of apparent in vivo toxicity for nilutamide in this same experiment,$^9$ and the lack of interaction of AH04 with the AR, suggests that the in vivo toxicity of these aryl hydantoin derivatives derives in part from androgen-independent mechanisms.

In summary, we confirmed the high antischistosomal efficacy of AH01 and showed that this aryl hydantoin is also effective against juvenile infections. Furthermore, AH01 had no measurable interaction with the AR in a ligand competition assay, but it did block DHT-induced cell proliferation in androgen-dependent human prostate cancer LNCaP cells. For AH01, nilutamide, and the other aryl hydantoins, there was no correlation between antischistosomal activity and androgen receptor interaction.

Although previous investigations$^6$ show that AH01 produces schistosome worm lesions similar to those seen after PZ treatment, the molecular mechanism of action of this or related aryl hydantoins is unknown. However, based on our data, their antischistosomal properties do not seem to derive from interactions with the host AR. Finally, it is interesting to note that although schistosome species do not appear to have

---

**Figure 1.** Aryl hydantoin structures.

**Figure 2.** Effects of aryl hydantoins on dihydrotestosterone (DHT)-induced LNCaP cell proliferation. Bars represent the mean ± SE of the average of 2–4 sets of independent duplicate experiments. Open bars: 10 μM compound alone; Filled bars: 10 μM compound + 10 nM DHT.

**Table 1**

<table>
<thead>
<tr>
<th>Infection</th>
<th>Compound</th>
<th>Dose (mg/kg)</th>
<th>Mean number of worms (SD)</th>
<th>Total worm burden reduction (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle control 1*</td>
<td>−</td>
<td>27.9 (12.5)</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Vehicle control 2*</td>
<td>−</td>
<td>17.4 (5.1)</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Vehicle control 3*</td>
<td>−</td>
<td>24.8 (5.2)</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Juvenile AH01</td>
<td>100</td>
<td>6.3 (4.3)‡</td>
<td>64‡</td>
<td></td>
</tr>
<tr>
<td></td>
<td>200</td>
<td>3.0 (1.9)§</td>
<td>88§</td>
<td></td>
</tr>
<tr>
<td>AH02</td>
<td>100</td>
<td>8.5 (6.8)‡</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td></td>
<td>200</td>
<td>3.3 (3.3)§</td>
<td>88§</td>
<td></td>
</tr>
<tr>
<td>Nilutamide∥</td>
<td>100</td>
<td>−</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>200</td>
<td>−</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Adult</td>
<td>AH01</td>
<td>100</td>
<td>1.5 (1.9)§</td>
<td>95§</td>
</tr>
<tr>
<td></td>
<td>AH02</td>
<td>100</td>
<td>1.3 (1.3)∥</td>
<td>93§</td>
</tr>
<tr>
<td>Nilutamide∥</td>
<td>100</td>
<td>−</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>PZ∥</td>
<td>100</td>
<td>−</td>
<td>18</td>
<td></td>
</tr>
</tbody>
</table>

*3% ethanol and 7% Tween 80 solubilizing vehicle.
†Versus vehicle control 2.
‡$P < 0.05$ from the Kruskal–Wallis test comparing the medians of the responses between the treatment and control groups.
§Versus vehicle control 1.
∥Versus vehicle control 3.
*Data from Reference 9.
PZ = praziquantel.
ARs, Fantappié and others discovered an expressed schistosome gene encoding the mitochondrial enzyme NADH ubiquinone oxidoreductase subunit 5 by screening a S. mansoni cDNA library with a human AR cDNA probe. This mitochondrial enzyme is thought to underlie the observed inhibition of S. mansoni growth by high concentrations of testosterone and dehydroepiandrosterone.

Received January 13, 2014. Accepted for publication March 7, 2014. Published online March 31, 2014.

Financial support: This investigation received financial support from the NIH (R21 AI097802-02) and the Swiss National Science Foundation (PPOOP3-135170 and 320030-149310).

Authors’ addresses: Chunkai Wang, Xiaofang Wang, Yuxiang Dong, and Jonathan L. Vennerstrom, Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, E-mails: chunkai.wang@unmc.edu, xiaofang.wang@unmc.edu, ydong@unmc.edu, and jvennerstrom@unmc.edu. Qingjie Zhao, Department of Pathology, University of Michigan, Ann Arbor, MI, E-mail: chemoq@gmail.com. Jaeki Min and R. Kiplin Guy, Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, Memphis, TN, E-mails: jaeki.min@stjude.org and kip.guy@stjude.org. Sakthivel Muniyan and Ming-Fong Lin, Department of Pathology, University of Nebraska Medical Center, Omaha, NE, E-mails: s.muniyan@unmc.edu and mlin@unmc.edu. Mireille Vargas and Jennifer Keiser, Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland, E-mails: mireille.vargas@unibas.ch and jennifer.keiser@unibas.ch.

REFERENCES